AI Maverick Intel, Inc. reports developments tied to its OTC-traded AI platform business, including its completed rebranding from Bionoid Pharma and adoption of the AIMV trading symbol. Company updates describe its focus on using the AI Maverick platform for customer acquisition, partner-led deal flow, and revenue-scaling activities.
Recurring news themes include material agreements, strategic acquisition-right frameworks, shareholder voting matters, governance updates, capital-structure disclosures, operating and financial results, and regulatory disclosures connected to the company’s public-company status.
AI Maverick Intel (AIMV) signed a definitive agreement to acquire all shares of Heal Access Canada from its controlling stockholder, HEAL Group.
Consideration comprises US$5 million, subject to adjustment, plus 20 million exchangeable shares, each exchangeable for one AIMV common share. The cash component will be satisfied through a secured vendor note bearing 10% annual simple interest and maturing two years after closing. AIMV will also assume approximately US$6.4 million owed to HEAL Group and affiliates.
Closing requires at least US$6 million in financing or binding commitments and independent special committee ratification. AIMV agreed to pursue financing by December 31, 2026; either party may terminate if closing has not occurred by February 28, 2027. Heal Access operates a healthcare AI platform live in five countries with more than 118,000 patients using it.
AI Maverick Intel (AIMV) has appointed healthcare executive Dr. Wayne Young to its Board of Directors and advanced its transition toward AI-enabled healthcare through a definitive agreement to acquire HEAL Access Canada Inc. from HEAL Group Holdings, subject to closing conditions.
The HEAL Access acquisition is described as the foundation of AIMV’s operating strategy, providing an initial healthcare platform around which the company plans to build AI-driven access, navigation and delivery solutions. AIMV also mutually rescinded its August 2024 transaction with Stronghold Media Group Corp., with related intellectual property reassigned to Stronghold, and plans a future corporate name change following required processes.
AI Maverick Intel (AIMV) issued 76,500,000 common shares to HEAL Group Holdings as the initial tranche under a Right of First Refusal Agreement effective February 11, 2026. The total ROFR consideration shares were adjusted to 100,000,000 for AIMV’s planned acquisition of HEAL Access Canada. AIMV also plans to seek an OTCQB Venture Market uplisting as part of its capital markets strategy.
AI Maverick Intel (AIMV) updated on HEAL Access Canada as it advances a proposed acquisition under a prior LOI. AIMV reports HEAL Access has >10 live customer implementations, 13 signed enterprise agreements, ~79 clinicians and ~118,000 connected patients across Canada, the UK, and the US.
The HEALix AI core supports clinical records, patient engagement, and case management with privacy frameworks (HIPAA, PHIPA, PIPEDA, GDPR). A definitive agreement remains subject to due diligence, final terms, and approvals.
AI Maverick Intel (AIMV) entered a non-binding LOI to acquire 100% of HEAL Access Canada (HAC) as the first transaction under a ROFR framework with HEAL.
Consideration would include 20,000,000 exchangeable AIMV shares and a secured vendor take-back note of ~USD$5.0 million; closing requires AIMV to have at least USD$5.0 million net positive working capital. Definitive agreement is targeted by May 29, 2026.
AI Maverick Intel (NASDAQ: AIMV) entered a Right of First Refusal agreement with HEAL Group Holdings effective February 11, 2026, giving AIMV the option to match third-party offers for certain HEAL assets during a defined exercise period.
AIMV will issue 120,000,000 common shares at a deemed price of US$0.02 per share (aggregate US$2.4 million) as consideration. The ROFR covers HEAL's AI-driven healthcare technology, services, and distribution businesses across more than six countries and remains in effect for three years unless mutually terminated.
AI Maverick Intel (OTC:AIMV) announced that effective Oct. 20, 2025 its common shares will trade under the new ticker AIMV following the company's rebranding from Bionoid Pharma to AI Maverick Intel.
The change aligns the market identity with the company's strategic focus on AI-driven customer acquisition, partner-led deal flow, and revenue acceleration via its AI Maverick platform. The company said its CUSIP and corporate structure remain unchanged and shareholders are not required to take any action. Management expects to finalize strategic JV initiatives in Q4 2025 to broaden commercialization and accelerate customer acquisition.